Vlad Hogenhuis, MD, is President and CEO of Chimera Bioengineering and brings more than 28 years of experience in oncology, immunology, and specialty pharma. Prior to joining Chimera, he served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline Plc., where he oversaw Oncology and Immunology. Prior to GSK, he served in leadership positions at Merck & Co. in the US, China, and Europe, where he was responsible for managing the P&L of specialty medicines. Before his roles in industry, Dr. Hogenhuis was a NIH Fellow at New England Medical Centre in Boston and a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the boards of Rezolute Bio (Nasdaq: RZLT), a public biotech company specializing in metabolic diseases, and GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats. He previously served as a member of the Board of Directors of Vision 2020, a program of the World Health Organization for the prevention of blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands. He received an MBA from The Wharton School of the University of Pennsylvania.